Trial Profile
Preliminary study on the effectiveness of low doses of Rituximab in patients with Graves orbitopathy (GO) poorly responding to immunosuppressive steroid treatment.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Feb 2022
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Graves ophthalmopathy
- Focus Registrational; Therapeutic Use
- 01 Jul 2014 New trial record